A. Tzontcheva

发表

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

N. Noulin, Susan Lu, M. Kitt, 2022, Pulmonary Therapy.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

L. Hanson, D. Dale, S. Huyck, 2015, Cytokine.

Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)

I. Pavord, S. Birring, J. Smith, 2020 .

Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

Christine R. Xu, P. Hodsman, D. Montgomery, 2018, Basic & clinical pharmacology & toxicology.

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

N. Noulin, Susan Lu, M. Kitt, 2022, Pulmonary Therapy.

An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism

R. Shankar, E. Nieschlag, H. Behre, 2017, Reproductive Biology and Endocrinology.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

G. Shapiro, M. Mita, Da Zhang, 2012, Cancer Chemotherapy and Pharmacology.

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

S. Bull, I. Andrulis, M. Blackstein, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

M. Dougados, D. M. van der Heijde, D. Heijde, 2015, Arthritis & rheumatology.

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

I. Pavord, S. Birring, J. Smith, 2022, The Lancet.

Responder Analyses for Patient-Reported Outcomes in a Pooled Analysis of Two Phase III Randomized Placebo Controlled Trials of Gefapixant, a P2X3 Receptor Antagonist for the Treatment of Chronic Cough

I. Pavord, S. Birring, A. Morice, 2021 .

Long-term Tolerability and Efficacy of Golimumab in Active Non-Radiographic Axial Spondyloarthritis: Results From Open-Label Extension.

M. Dougados, W. Maksymowych, J. Sieper, 2021, Rheumatology.

Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study

S. Bull, I. Andrulis, M. Blackstein, 2006, Breast Cancer Research.

THU0238 A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis

M. Dougados, D. M. van der Heijde, J. Boice, 2015 .

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

O. Rascol, C. Lines, R. Hauser, 2017, Neurology.

Demographic, Clinical, and Patient-Reported Outcome Data From Two Global, Phase 3 Trials of Chronic Cough.

I. Pavord, S. Birring, J. Smith, 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

L. Hanson, D. Dale, S. Huyck, 2015, Cytokine.